Biotech entity

GoodRx

Company GDRX

Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Churchill Downs Incorporated, the most common co-covered peer. The tracked stories average 7.5 original sources each. GoodRx appears in 2 tracked Biotech stories from February 26, 2026.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · GoodRx

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about GoodRx

Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention Churchill Downs Incorporated, the most common co-covered peer. The tracked stories average 7.5 original sources each. GoodRx appears in 2 tracked Biotech stories from February 26, 2026.

Stories tracked
2
Sources per story
7.5

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering GoodRx. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning GoodRx 2

Pharma Neutral

Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.

12 sources
Pharma Neutral

GoodRx and Schrödinger Report 2025 Results Amid Shifting Pharma Tech Landscape

GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.

3 sources

GoodRx is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.